PSMA PET/CT and radiotherapy in prostate cancer: a winning team

[11] Rajcic B(2001)Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) J Med Chem 44 688-697

[12] Foreman D(2012)Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjug Chem 23 523-528

[13] Moretti K(2021)High detection rate in [18 F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients Ann Nucl Med 35 2951-2959

[14] O'Callaghan ME(2021)Prospective comparison of 18 F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer Eur J Nucl Med Mol Imaging 48 903-913

[15] Narang K(2020)Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls Clin Radiol 75 1085-1086

[16] Kadian M(2012)[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur J Nucl Med Mol Imaging 39 790-813

[17] Venkatesan K(2019)EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study) Eur Urol 76 668-674

[18] Mishra S(2015)Evaluation of hybrid J Nucl Med 56 1400-1406

[19] Bisht S(2016)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy Eur J Nucl Med Mol Imaging 43 676-677

[20] Gupta D(2020)Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer J Nucl Med 61 214-219

[11] Rajcic B(2001)Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) J Med Chem 44 688-697

[12] Foreman D(2012)Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjug Chem 23 523-528

[13] Moretti K(2021)High detection rate in [18 F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients Ann Nucl Med 35 2951-2959

[14] O'Callaghan ME(2021)Prospective comparison of 18 F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer Eur J Nucl Med Mol Imaging 48 903-913

[15] Narang K(2020)Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls Clin Radiol 75 1085-1086

[16] Kadian M(2012)[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur J Nucl Med Mol Imaging 39 790-813

[17] Venkatesan K(2019)EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study) Eur Urol 76 668-674

[18] Mishra S(2015)Evaluation of hybrid J Nucl Med 56 1400-1406

[19] Bisht S(2016)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy Eur J Nucl Med Mol Imaging 43 676-677

[20] Gupta D(2020)Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer J Nucl Med 61 214-219